A federal appeals court ruled unanimously Wednesday that an antitrust class action lawsuit, in which two health clinics alleged four [...] …
Category: General
The U.S. Department of Health and Human Services (HHS) touted the agency’s recently announced plan to pilot a 340B rebate [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A Washington D.C. federal court this week rejected the Department of Health and Human Services’ (HHS) request to partially dismiss [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
President Donald Trump is urging more than a dozen leading pharmaceutical manufacturers to begin implementing his proposed “most-favored nation” (MFN) [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A key Senate Republican and outspoken 340B critic recently argued that any comprehensive efforts to address healthcare affordability in Congress [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A North Carolina-based drugmaker recently tightened its 340B contract pharmacy restrictions to limit distribution of a pulmonary arterial hypertension treatment—just [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Editor’s Note: With 340B-related litigation heating up in several states following the enactment of new contract pharmacy access laws, 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
340B covered entities and drugmakers offered competing criticisms Thursday of the Health Resources and Services Administration’s (HRSA) newly released 340B [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Three federal appeals judges—who have all ruled on 340B matters in the past—will hear oral arguments in September in a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A majority of 340B hospitals surveyed said the costs associated with implementing drugmakers’ proposed rebate models would hinder their ability [...] …